Search company, investor...

Wugen

wugen.com

Founded Year

2018

Stage

Series B | Alive

Total Raised

$208M

Last Raised

$172M | 1 yr ago

About Wugen

Wugen is a biotechnology company that develops cell therapies for the treatment of T-cell leukemias and lymphomas, acute myeloid leukemia (AML) and multiple myeloma (MM).

Headquarters Location

4340 Duncan Ave Suite 302

Saint Louis, Missouri, 63110,

United States

Missing: Wugen's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Wugen's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Wugen

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Wugen is included in 1 Expert Collection, including Regenerative Medicine.

R

Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

Wugen Patents

Wugen has filed 1 patent.

The 3 most popular patent topics include:

  • Cancer treatments
  • Clusters of differentiation
  • Immune system
patents chart

Application Date

Grant Date

Title

Related Topics

Status

11/8/2019

Clusters of differentiation, Olfactory receptors, Immune system, Immunology, Cancer treatments

Application

Application Date

11/8/2019

Grant Date

Title

Related Topics

Clusters of differentiation, Olfactory receptors, Immune system, Immunology, Cancer treatments

Status

Application

Latest Wugen News

Wugen to Present at the Upcoming Jefferies London Healthcare Conference

Nov 10, 2022

November 10, 2022 08:00 AM Eastern Standard Time ST. LOUIS & SAN DIEGO--( BUSINESS WIRE )-- Wugen, Inc., a clinical-stage biotechnology company developing a pipeline of allogeneic cell therapies to treat a broad range of hematological and solid tumor malignancies, today announced that management will present at 9:45 a.m. GMT (4:45 a.m. ET) on Thursday, November 17, 2022 at the upcoming Jefferies London Healthcare Conference. About Wugen Wugen, Inc., is a clinical-stage biotechnology company developing the next generation of off-the-shelf memory natural killer (NK) and CAR-T cell therapies for cancer. Wugen is leveraging its proprietary Moneta™ platform and deep genomic engineering expertise to pioneer a new class of memory NK cell therapies to treat hematological and solid tumor malignancies. For more information, please visit www.wugen.com . Contacts

Wugen Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Wugen Rank

Wugen Frequently Asked Questions (FAQ)

  • When was Wugen founded?

    Wugen was founded in 2018.

  • Where is Wugen's headquarters?

    Wugen's headquarters is located at 4340 Duncan Ave, Saint Louis.

  • What is Wugen's latest funding round?

    Wugen's latest funding round is Series B.

  • How much did Wugen raise?

    Wugen raised a total of $208M.

  • Who are the investors of Wugen?

    Investors of Wugen include RiverVest Venture Partners, LYZZ Capital, Tybourne Capital Management, ICG, Fidelity Investments and 10 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.